ArticleCardiovascular research2024
Plasma adiponectin levels and risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: large-scale observational and Mendelian randomization evidence.
Article in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction.Cardiovascular diabetology · 2025Trial
- Blood-based obesity biomarkers and their relevance for disease risk.Nature reviews. Endocrinology · 2026Review
- Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury.Advanced healthcare materials · 2026Article
- Imaging and biomarker-based risk stratification in TAVI: the role of epicardial fat, visceral fat, and adiponectin.European heart journal open · 2026Article
- Recent Insights Into Circulating Adipokines in Obesity: Systematic Review and Meta-Analysis.Obesity science & practice · 2026Review
- Large-Scale Proteomic Profiling of Incident Heart Failure and Its Subtypes in Older Adults.Circulation. Genomic and precision medicine · 2026Article
- Chemerin Normal Function and Roles in Metabolic and Nonmetabolic Disorders: An Up-To-Date Comprehensive Review.Biochemistry research international · 2026Review
- Longitudinal associations of serum Irisin and adiponectin with incident metabolic syndrome in middle-aged and older adults over three years.Scientific reports · 2025Article
- Observational
- The Role of Adiponectin andGenes · 2025Review
- The correlation between proprotein convertase subtilisin/kexin type 9 and adiponectin in the progression from prediabetes to type 2 diabetes mellitus.Scientific reports · 2025Article
- Potential of plasma biomarkers for heart failure prediction, management, and prognosis: A multiomics perspective.Heart failure reviews · 2025Review
- Key inflammatory players for infarcted mass and cardiac remodeling after acute myocardial infarction.Frontiers in cardiovascular medicine · 2025Review
- Investigating the potential impact of sex hormones and adiponectin on the risk of liver fibrosis and cirrhosis: a Mendelian randomization study.Archives of medical science : AMS · 2025Article
- High-Fat Diet Augments Myocardial Inflammation and Cardiac Dysfunction in Arrhythmogenic Cardiomyopathy.Nutrients · 2024Article
- Appraising associations between signature lipidomic biomarkers and digestive system cancer risk: novel evidences from a prospective cohort study of UK Biobank and Mendelian randomization analyses.Lipids in health and disease · 2024Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
aimsAdiponectin may play an important protective role in heart failure and associated cardiovascular diseases. We hypothesized that plasma adiponectin is associated observationally and causally, genetically with risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction. METHODS AND
resultsIn the Copenhagen General Population Study, we examined 30 045 individuals with plasma adiponectin measurements observationally and 96 903 individuals genetically in one-sample Mendelian randomization analyses using five genetic variants explaining 3% of the variation in plasma adiponectin. In the HERMES, UK Biobank, The Nord-Trøndelag Health Study (HUNT), deCODE, the Michigan Genomics Initiative (MGI), DiscovEHR, and the AFGen consortia, we performed two-sample Mendelian randomization analyses in up to 1 030 836 individuals using 12 genetic variants explaining 14% of the variation in plasma adiponectin.In observational analyses modelled linearly, a 1 unit log-transformed higher plasma adiponectin was associated with a hazard ratio of 1.51 (95% confidence interval: 1.37-1.66) for heart failure, 1.63 (1.50-1.78) for atrial fibrillation, 1.21 (1.03-1.41) for aortic valve stenosis, and 1.03 (0.93-1.14) for myocardial infarction; levels above the median were also associated with an increased risk of myocardial infarction, and non-linear U-shaped associations were more apparent for heart failure, aortic valve stenosis, and myocardial infarction in less-adjusted models. Corresponding genetic, causal risk ratios were 0.92 (0.65-1.29), 0.87 (0.68-1.12), 1.55 (0.87-2.76), and 0.93 (0.67-1.30) in one-sample Mendelian randomization analyses, and no significant associations were seen for non-linear one-sample Mendelian randomization analyses; corresponding causal risk ratios were 0.99 (0.89-1.09), 1.00 (0.92-1.08), 1.01 (0.79-1.28), and 0.99 (0.86-1.13) in two-sample Mendelian randomization analyses, respectively.
conclusionObservationally, elevated plasma adiponectin was associated with an increased risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction. However, genetic evidence did not support causality for these associations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.